– CANADA, ON – Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce the appointment of Samira Sakhia (B.Comm., MBA, CPA) to its Board of Directors.
Ms. Sakhia has been the CFO of Paladin Labs Inc. since 2002, where she is responsible for leading the finance, operations, human resources, and investor relations teams. Ms. Sakhia has been a key member of the management team at Paladin and closely involved in the company’s strategy of in-licensing, acquiring products, and acquiring other specialty pharmaceutical companies in Canada and abroad. During her tenure, Paladin achieved remarkable growth, increasing in value from $75 million to over $3 billion in 2014 when it was acquired by Endo International plc.
Prior to joining Paladin, Ms. Sakhia held several leadership positions at Discreet Logic Inc. including Controller of North American Operations, Manager of International Financial Reporting (Montreal, Quebec), and European Financial Manager (London, England). Prior to working at Discreet Logic, Ms. Sakhia worked as an auditor at Arthur Andersen & Co.
Ms. Sakhia holds a Bachelor of Commerce degree in Finance and Accounting, and an MBA in Strategy and Marketing, all from McGill University.
In addition, Ms. Sakhia is a Canadian-designated Chartered Professional Accountant. Ms. Sakhia was the recipient of the 2014 Aces of Finance Award from the Quebec Chapter of the Financial Executive Institute of Canada in the “Financial executive of a small or medium sized enterprise” category.
Walt Macnee, Antibe’s Chairman, said “We are delighted to add Ms. Sakhia to the Antibe Board. Her pharmaceutical industry expertise and financial acumen will be a tremendous asset to us as we grow.”
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected new pharmaceuticals that are improved versions of existing drugs. These improvements are based on Nobel Prize-winning medical research highlighting the crucial role of gaseous mediators, chemical substances produced in the human body to regulate a range of fundamental cellular processes. The Corporation’s drug design approach involves chemically linking an existing off-patent drug (“base drug”) to an Antibe-patented, hydrogen sulfide-releasing molecule. For medical conditions characterized by inflammation, pain or vascular dysfunction, this design approach can efficiently produce improved versions of a number of existing drugs. Notably, Antibe’s products are themselves fully patent-protectable and may benefit from the predictable toxicity and effectiveness profiles of the base drug.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.